Amgen has reported disappointing results in the clinical trial of MariTide, its weight loss drug candidate. According to the study data, the 592 participants achieved an average weight loss of 20% of their body weight. While this result is comparable to Novo Nordisk's Wegovy (15%) and Eli Lilly's Zepbound (22%), it offers no significant advantages over its competitors.
Additionally, 11% of patients discontinued the trial due to side effects, exceeding the 6% recorded by other treatments. However, a distinguishing feature of MariTide is its application, which can be administered monthly or every two months, offering greater convenience to patients.
Markets reacted negatively to the news, causing a decline in Amgen's stock price. Competition in the weight loss market continues to intensify, with expectations for new treatments such as Novo Nordisk's CagriSema and Eli Lilly's Retatrutide, which promise at least 25% weight loss, a goal that MariTide did not achieve.
This result represents a challenge for Amgen in a segment that has seen rapid innovations and growing expectations from consumers and investors.
From good ideas to action
To communicate with charisma and effective leadership, it is essential to overcome the obstacles that limit the expression of powerful ideas.
If you are concerned that your message is not reaching with the necessary force or that your words are not igniting that "spark" in your audience, our masterclass "Storyleading: How to Communicate with Charisma, 'Flare' and 'Spark'" is the ideal opportunity.